- Home
- TRVI vs RCEL Comparison
TRVI vs RCEL Comparison
Compare TRVI & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRVI
- RCEL
- Stock Information
- Founded
- TRVI 2011
- RCEL N/A
- Country
- TRVI United States
- RCEL United States
- Employees
- TRVI N/A
- RCEL N/A
- Industry
- TRVI Biotechnology: Pharmaceutical Preparations
- RCEL Medical/Dental Instruments
- Sector
- TRVI Health Care
- RCEL Health Care
- Exchange
- TRVI Nasdaq
- RCEL Nasdaq
- Market Cap
- TRVI 363.7M
- RCEL 308.6M
- IPO Year
- TRVI 2019
- RCEL N/A
- Fundamental
- Price
- TRVI $4.60
- RCEL $9.75
- Analyst Decision
- TRVI Strong Buy
- RCEL Buy
- Analyst Count
- TRVI 8
- RCEL 5
- Target Price
- TRVI $9.31
- RCEL $17.25
- AVG Volume (30 Days)
- TRVI 739.7K
- RCEL 191.4K
- Earning Date
- TRVI 03-19-2025
- RCEL 02-13-2025
- Dividend Yield
- TRVI N/A
- RCEL N/A
- EPS Growth
- TRVI N/A
- RCEL N/A
- EPS
- TRVI N/A
- RCEL N/A
- Revenue
- TRVI N/A
- RCEL $64,251,000.00
- Revenue This Year
- TRVI N/A
- RCEL $62.11
- Revenue Next Year
- TRVI N/A
- RCEL $31.19
- P/E Ratio
- TRVI N/A
- RCEL N/A
- Revenue Growth
- TRVI N/A
- RCEL 28.14
- 52 Week Low
- TRVI $2.30
- RCEL $7.51
- 52 Week High
- TRVI $5.05
- RCEL $18.93
- Technical
- Relative Strength Index (RSI)
- TRVI 62.80
- RCEL 50.10
- Support Level
- TRVI $3.93
- RCEL $8.37
- Resistance Level
- TRVI $4.14
- RCEL $11.25
- Average True Range (ATR)
- TRVI 0.29
- RCEL 0.55
- MACD
- TRVI 0.06
- RCEL 0.22
- Stochastic Oscillator
- TRVI 64.82
- RCEL 47.92
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.